COMMUNIQUÉS West-GlobeNewswire

Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
23/06/2026
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company [...]
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23/06/2026
Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in [...]
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
23/06/2026
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO Platform KUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group [...]
Ichnos Glenmark Innovation (IGI) Announces Appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer
23/06/2026
Physician-Scientist with Proven Track Record of Global Drug Development and Regulatory Approvals to Lead Clinical Development of IGI’s Multispecific™ Oncology Pipeline NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Ichnos [...]
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
23/06/2026
Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin Company intends to file the Phase 3 protocol in Q3 2026 and is actively [...]
Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults
23/06/2026
U.S. Phase 2 trial met primary endpoints, with up to 11.5% weight loss at 36 weeks, showing continued weight reduction at a consistent rate and no evidence of a slowing trajectory CX11 demonstrated favorable GI [...]
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
23/06/2026
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy [...]
Persephone Biosciences’ Science-Backed Infant and Toddler Synbiotics Now Available on Amazon
23/06/2026
- Clinically researched synbiotics developed from findings published in Cell Host & Microbe and Communications Biology now available through Amazon, with TikTok Shop expansion planned next month - - Prime Day [...]
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the [...]
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
23/06/2026
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra [...]
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
23/06/2026
Combined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K (PiZZ [...]
Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors
23/06/2026
A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced-proximity therapeutics. Dr. Houston's deep experience with protein [...]
ApolloMD Welcomes 2026 Emergency Medicine Administrative Fellows and Opens Applications for Next Class
23/06/2026
ATLANTA, June 23, 2026 (GLOBE NEWSWIRE) -- ApolloMD proudly welcomes Nishant Gogna, DO, and Eun Sung “Kevin” Kim, MD, as the incoming physicians for its Emergency Medicine Administrative Fellowship program. ApolloMD [...]
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
23/06/2026
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM [...]
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
23/06/2026
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes MissionEB Phase 2 data as [...]
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
23/06/2026
REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
CoreHealth Announces Leadership Transition as Charles Martin Appointed Chief Executive Officer
23/06/2026
TORONTO, June 23, 2026 (GLOBE NEWSWIRE) -- CoreHealth Technologies Inc. today announced that Michael Peters will conclude his tenure as Chief Executive Officer at the end of June, following five years of leadership that [...]
Integra LifeSciences Announces Key Executive Appointments
23/06/2026
Leadership appointments reinforce company’s commitment to enhancing commercial execution and deepening customer engagement, while building leadership depth PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra [...]

Pages